创新药产业链表现良好,百济神州、诺诚健华、恒瑞医药等持续活跃

动脉网
Yesterday

创新药产业链表现强劲,多家企业如百济神州、诺诚健华和恒瑞医药等持续活跃。百济神州2024年营收同比增长56.19%,核心产品泽布替尼和替雷利珠单抗收入显著增长,预计2025年实现全年经营利润为正。诺诚健华的BCL2抑制剂ICP-248片拟纳入突破性治疗品种,奥布替尼新适应症获批用于一线治疗CLL/SLL。锦波生物2024年营收同比增长84.92%。机构看好创新药产业链在2024年的持续良好表现,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10